Lineage Cell Therapeutics Future Growth

Future criteria checks 2/6

Lineage Cell Therapeutics is forecast to grow earnings and revenue by 50.3% and 63.5% per annum respectively while EPS is expected to grow by 51.1% per annum.

Key information

50.3%

Earnings growth rate

51.1%

EPS growth rate

Biotechs earnings growth	34.9%
Revenue growth rate	63.5%
Future return on equity	n/a
Analyst coverage	Good
Last updated	20 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:BT3 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	16	-34	-36	N/A	6
12/31/2025	8	-26	-30	N/A	7
12/31/2024	5	-28	-23	3	6
6/30/2024	6	-24	-22	-22	N/A
3/31/2024	8	-24	-24	-23	N/A
12/31/2023	9	-21	-29	-29	N/A
9/30/2023	9	-23	-31	-31	N/A
6/30/2023	11	-22	-32	-31	N/A
3/31/2023	12	-24	-33	-32	N/A
12/31/2022	15	-26	1	1	N/A
9/30/2022	14	-49	3	3	N/A
6/30/2022	13	-51	4	4	N/A
3/31/2022	9	-49	5	6	N/A
12/31/2021	4	-43	-24	-24	N/A
9/30/2021	4	-12	-24	-23	N/A
6/30/2021	2	-12	-24	-23	N/A
3/31/2021	2	-14	-22	-22	N/A
12/31/2020	2	-21	-20	-20	N/A
9/30/2020	3	-27	-20	-20	N/A
6/30/2020	3	-36	-22	-22	N/A
3/31/2020	3	-59	-28	-28	N/A
12/31/2019	4	-12	-32	-32	N/A
9/30/2019	3	-52	-34	-32	N/A
6/30/2019	3	31	-35	-32	N/A
3/31/2019	5	57	-32	-30	N/A
12/31/2018	5	-46	-34	-31	N/A
9/30/2018	5	-73	-33	-31	N/A
6/30/2018	6	-125	-33	-31	N/A
3/31/2018	4	-133	N/A	-33	N/A
12/31/2017	3	-20	N/A	-31	N/A
9/30/2017	4	47	N/A	-34	N/A
6/30/2017	3	64	N/A	-35	N/A
3/31/2017	4	100	N/A	-36	N/A
12/31/2016	6	34	N/A	-42	N/A
9/30/2016	6	25	N/A	-47	N/A
6/30/2016	7	-20	N/A	-50	N/A
3/31/2016	8	-54	N/A	-50	N/A
12/31/2015	7	-47	N/A	-45	N/A
9/30/2015	7	-45	N/A	-40	N/A
6/30/2015	6	-39	N/A	-37	N/A
3/31/2015	5	-39	N/A	-38	N/A
12/31/2014	5	-36	N/A	-39	N/A
9/30/2014	5	-45	N/A	-38	N/A
6/30/2014	5	-46	N/A	-36	N/A
3/31/2014	5	-44	N/A	-33	N/A
12/31/2013	4	-44	N/A	-30	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BT3 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BT3 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BT3 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BT3's revenue (63.5% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: BT3's revenue (63.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BT3's Return on Equity is forecast to be high in 3 years time

Lineage Cell Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Recent updates

Insufficient new directors

Lineage Cell Therapeutics, Inc. Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance, at the 59th Annual Inner Ear Biology Workshop

Insufficient new directors

Lineage Cell Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Insufficient new directors

New minor risk - Profitability

First quarter 2024 earnings released: US$0.036 loss per share (vs US$0.026 loss in 1Q 2023)

Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Insufficient new directors

Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors

No longer forecast to breakeven

Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

No longer forecast to breakeven

New minor risk - Profitability

No longer forecast to breakeven

Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting

Full year 2023 earnings released: US$0.12 loss per share (vs US$0.15 loss in FY 2022)

Lineage Cell Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Lineage Cell Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury

Independent Director recently bought €93k worth of stock

Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $14.000002 million.

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Third quarter 2023 earnings released: US$0.041 loss per share (vs US$0.036 loss in 3Q 2022)

Lineage Cell Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Lineage Cell Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501

Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies